Navigation Links
EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
Date:4/11/2008

Oral Presentation During the "New Drugs on the Horizon 2" Special Session

ROCKVILLE, Md., April 11 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced it will present preclinical data for its product candidates ENMD-2076, MKC-1, and ENMD-1198. The data will be presented by EntreMed scientists and collaborators during the American Association for Cancer Research (AACR) Annual Meeting being held April 12-16, 2008 in San Diego, California.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mark R. Bray, Ph.D., EntreMed Vice President, Research, will give an oral presentation on the Company's selective kinase inhibitor, ENMD-2076, during the special session, "New Drugs on the Horizon 2." EntreMed will share the podium with representatives from leading pharmaceutical companies during this special session which provides early disclosure of new small molecules that are nearing or have recently advanced into clinical trials. Dr. Bray's presentation is scheduled for Sunday, April 13, 2008, at 3:15 p.m.

ENMD-2076 is selective kinase inhibitor with potent activity against Aurora A and tyrosine kinases linked to promoting cancer and inflammatory diseases. ENMD-2076 acts through multiple pathways resulting in antiproliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated substantial, dose-dependent efficacy as a single agent in multiple xenograft models, including tumor regression in breast, colon, and leukemia models. Importantly, ENMD-2076 is an oral agent that has sho
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
2. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
3. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
4. EntreMed to Present at The New York Society of Security Analysts Industry Conference
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
7. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
8. EntreMed Raises $20 Million to Support Clinical Development Program
9. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
10. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting
11. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft tissue ... Phase 2 clinical trial.  This open-label study will assess ... (an investigational medication), in approximately 30 adults as first-line ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 is ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held medical ... an exclusive distributor agreement with ITOCHU Corporation (Tokyo Stock ... system for the treatment of cancer in ... is the world,s first and only MRI-guided radiation therapy ...
(Date:1/22/2015)... RMD ) today announced results for its quarter ended ... a 10 percent increase compared to the quarter ended December ... basis). Net income was $91.2 million, an increase of 5 ... earnings per share for the quarter were $0.64, an increase ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
... presentations demonstrate the safety and activity of ... MYCAMINE as an antifungal ... pooled analysis of 17,clinical studies demonstrate that MYCAMINE(R) (micafungin sodium) ... all ages with serious, underlying diseases with,immunosuppressed status. These studies, ...
... Sept. 18 Worldwide markets of,approved EGFr/HEr2 inhibitors grew ... to more than $3.2 billion, exceeding total sales reported ... expanding,indications for these drugs and fueling continued rapid market ... than 50 novel,agents targeting this pathway are in development. ...
Cached Medicine Technology:New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile 2New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile 3New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile 4
(Date:1/22/2015)... U.S. Pharmacopeial Convention is pleased to announce that Gigi ... North Carolina State’s College of Veterinary Medicine has been ... Distinguished Volunteer Service—the organization’s highest award. , Since ... experts to direct its work to improve the health ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Woodloch Pines, an ... has been selected by TripAdvisor as the number one best ... 6th best in the world for their annual Travelers’ Choice ... travel community . The website is home to millions of ...
(Date:1/22/2015)... Houston, TX (PRWEB) January 22, 2015 The ... Pro Bodybuilder Ben Pakulski to increase lean muscle by up ... This has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting ... shows that it is a step-by-step, scientific diet formula that ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the main ... , Auto insurance quotes help many drivers find the ... to call an agent or visit an agency for price ... website: http://autocarinsurancebest.com/ . , Every business who relies heavily ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2
... in the United States between 1999 and 2006, climbing ... overdoses combined. Hospitalizations and emergency room visits related to ... Oxycontin) and hydrocodone (Vicodin) also increased dramatically in the ... August issue of Health Affairs describes a ...
... Aug. 3 (HealthDay News) -- Pregnant women who take ongoing, ... be at increased risk of having babies with birth defects, ... drug is used to treat yeast infections of the vagina, ... treat meningitis caused by a certain type of fungus and ...
... HealthDay Reporter , WEDNESDAY, Aug. 3 (HealthDay News) -- A ... lung function in patients who haven,t been helped with standard ... in asthma, and appears to be the first drug to ... a professor of medicine in the pulmonary and critical care ...
... -- Obesity counseling should focus on neurobehavioral processes -- ... to biological and environmental factors -- instead of personal ... Rush University Medical Center in Chicago outlines their new ... Journal of the American Dietetic Association . "Typically, ...
... (GSA) the nation,s largest interdisciplinary organization devoted to the ... Aging (NCCA) have chosen Barry Bittman, MD, of the Yamaha ... Gene D. Cohen Research Award in Creativity and Aging. ... Cohen, MD, whose research in the field of creativity and ...
... largest interdisciplinary organization devoted to the field of aging ... 2011 recipient of the Distinguished Mentorship in Gerontology Award. ... fostered excellence in the field, but have made a major ... sought by students and colleagues. To be eligible, the mentor ...
Cached Medicine News:Health News:Group Health establishes major initiative to prevent opioid abuse and overdose 2Health News:Group Health establishes major initiative to prevent opioid abuse and overdose 3Health News:High Dose of Yeast Infection Drug Linked to Birth Defects, FDA Says 2Health News:Experimental Drug Promising Against Tough-to-Treat Asthma 2Health News:Obesity Counseling Should Stress Brain, Not Willpower: Study 2Health News:Bittman to receive 2011 Gene D. Cohen Award 2Health News:Ferraro to receive GSA's 2011 Distinguished Mentorship in Gerontology Award 2
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
... special order products are offered as 1-piece ... lengths. The modular instruments may be customized ... such as ratchets, insulation and flush ports. ... stock. Customer specifications may affect delivery times. ...
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
Medicine Products: